Duan, Yajian
Wu, Wenyi
Cui, Jing
Matsubara, Joanne Aiko
Kazlauskas, Andrius
Ma, Gaoen
Li, Xiaorong
Lei, Hetian
Funding for this research was provided by:
Health Commission of Shanxi Province (2020004)
Research Project Supported by Shanxi Scholarship Council of China (2022-203)
Shanxi Bethune Hospital Foundation (2021RC005)
Shanxi Bethune Hospital Education and Teaching Reform Foundation (2022Jx22)
Natural Science Foundation of Shanxi province (202103021224345)
Natural Science Foundation of Hunan Province (2021JJ41030)
National Natural Science Foundation of China (82171085, 82070989)
Natural Science Foundation of Tianjin City (19JCZDJC64000)
Introduction plan of high-level foreign experts (G2022026027L)
Article History
Received: 27 December 2022
Accepted: 17 July 2023
First Online: 3 August 2023
Declarations
:
: Collection of epiretinal membranes from patients with proliferative vitreoretinopathy for this study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Vancouver Hospital and University of British Columbia Clinical Research Ethics Board. Informed consent was obtained from all subjects involved in the study. The protocol for the use of animals was approved by the Schepens Eye Research Institute Animal Care and Use Committee (Boston, MA), and all animal surgeries adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and followed the ARRIVE guidelines (ExternalRef removed).
: All the authors agree with this publication.
: The authors declare no competing interests.